Acceleron Pharma Science & Pipeline

Science & Pipeline

Hematology

Hematology

REBLOZYL®
(luspatercept-aamt)

Phase 1Ph1Phase 2Ph2Phase 3Ph3ApprovedApp
REBLOZYL® (luspatercept-aamt)
Beta-Thalassemia**
Beta-Thalassemia**
luspatercept-aamt
luspatercept-aamt

Beta-Thalassemia

non-transfusion dependent

Beta-Thalassemia

non-transfusion dependent

BEYOND Trial*BEYOND Trial*
Myelodysplastic Syndromes
Myelodysplastic
Syndromes
MEDALIST Trial*MEDALIST Trial*
COMMANDS Trial*COMMANDS Trial*
Myelofibrosis
Myelofibrosis
INDEPENDENCE Trial (planned)*INDEP Trial (planned)*

* Bristol-Myers Squibb-sponsored

** Reblozyl is approved in the United States for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions. It is not approved for any use in any other country.

Pulmonary

Sotatercept
Phase 1Ph1Phase 2Ph2Phase 3Ph3ApprovedApp

Pulmonary

Sotatercept
 
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
PULSAR TrialPULSAR Trial
SPECTRA Exploratory TrialSPECTRA Trial
ACE-1334
Pulmonary Disease
Pulmonary Disease

Neuromuscular

ACE-083
Phase 1Ph1Phase 2Ph2Phase 3Ph3ApprovedApp

Neuromuscular

ACE-083
Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease
Ph2 TrialPh 2